ZUG, Switzerland, Oct. 17,
2023 /PRNewswire/ -- SHL Medical ("SHL"), a
world-leading solutions provider of advanced drug delivery systems
such as autoinjectors and innovative specialty delivery systems,
has entered into a non-exclusive co-marketing partnership agreement
with Lifecore Biomedical (Nasdaq: LFCR) ("Lifecore"), a fully
integrated Contract Development and Manufacturing Organization
("CDMO") that offers highly differentiated capabilities in the
development, fill and finish of complex sterile injectable
pharmaceutical products in syringes and vials.
Through this partnership, Lifecore becomes a member of SHL's
recently announced Alliance Management program, an
initiative created to further strengthen SHL's vertically
integrated business model by facilitating customer engagement with
other key players within the drug delivery ecosystem.
SHL and Lifecore will, pursuant to the terms of its agreement,
exchange knowledge and experience in their respective fields,
enabling both companies to provide their customers unparalleled
guidance in CDMO services and best-in-class options for drug
delivery device development.
As the leader and pioneer of autoinjectors, SHL offers drug
delivery device solutions and vertically integrated capabilities
for the development, manufacturing, and final assembly of its
autoinjector products. The partnership with Lifecore will allow SHL
to recommend a trusted CDMO renowned for its proven proficiency and
robust quality systems in aseptic pharmaceutical manufacturing and
primary container filling, creating a comprehensive support system
across all stages of the autoinjector development and commercial
lifecycle.
"As a true partner to pharma and biotech, we believe in
providing full end-to-end solutions that enhance patients' quality
of life and enable patients' independence," said Kimberlee Steele, Managing Director of SHL
Pharma, SHL Medical's final assembly, labeling, and packaging
business unit in Florida. "We are
excited to partner with Lifecore to provide high-quality CDMO
services matching SHL's own high-touch approach to servicing our
customers."
Darren Hieber, Senior Vice
President of Corporate Development and Partnerships for Lifecore
commented, "We are continuously adapting to keep pace with the
evolution of healthcare treatments and technologies and our deep
expertise in the fill/finish of syringes and vials is a perfect
match for SHL's products. Our relationship with SHL will expand the
breadth of our offerings to our CDMO customers, enabling them to
deliver the benefits and convenience of innovative drug delivery
systems to their patients worldwide. We are excited to be aligned
with an industry leader, who has created a business focused on
patient-centric solutions through their unique, convenient,
high-quality product portfolio."
- Picture is available at AP -
About SHL Medical
As a world-leading solutions
provider of advanced drug delivery systems, SHL Medical is the
partner of choice for many leading pharma and biotech companies.
Driven by its company purpose – Enabling Patients' Independence –
SHL Medical offers patient-centric solutions for the design,
development, and manufacturing of autoinjectors, pen injectors, as
well as innovative specialty delivery systems for large-volume and
high-viscosity formulations. It also offers final assembly,
labeling, and packaging solutions for its drug delivery
systems.
In response to the rising trend in home therapy, SHL Medical has
increased its developmental work in the digital healthcare sector
to help improve the drug delivery ecosystem.
Located across Switzerland,
Taiwan, Sweden, and the US, SHL Medical's global team
of experts collaborate seamlessly as one team in utilizing its
comprehensive in-house manufacturing capabilities. The company's
solutions offer customization and optimization for each project
while proactively weaving sustainability-driven measures into its
designs and processes to contribute to a cleaner earth. For
additional information, visit www.shl-medical.com.
About Lifecore Biomedical
Lifecore Biomedical, Inc. is
a fully integrated contract development and manufacturing
organization (CDMO) that offers highly differentiated capabilities
in the development, fill and finish of complex sterile injectable
pharmaceutical products in syringes and vials. As a leading
manufacturer of premium, injectable grade Hyaluronic Acid, Lifecore
brings more than 40 years of expertise as a partner for global and
emerging biopharmaceutical and biotechnology companies across
multiple therapeutic categories to bring their innovations to
market. For more information about the Company, visit Lifecore's
website at www.lifecore.com.
Media contact
Carl Gillblad
Communications and Marketing Operations
info@shl-medical.com
+41 41 368 00 00
Alliance Management contact
Alina Smotrova
Corporate Development
alliance@shl-medical.com
+41 41 368 00 00
Lifecore Investor Relations
Jeff Sonnek
jeff.sonnek@icrinc.com
(646) 277-1263
Important Cautions Regarding Forward-Looking
Statements
This press release contains forward-looking
statements regarding future events and future results, including
the anticipated business relationship between SHL and Lifecore,
that are subject to the safe harbor created under the Private
Securities Litigation Reform Act of 1995 and other safe harbors
under the Securities Act of 1933 and the Securities Exchange Act of
1934. Words such as "anticipate", "estimate", "expect", "project",
"plan", "intend", "believe", "may", "might", "will", "should", "can
have", "likely" and similar expressions are used to identify
forward-looking statements. All forward-looking statements involve
certain risks and uncertainties that could cause actual results to
differ materially, including such factors among others, the nature
and requirements of the relationship between SHL and Lifecore, the
ability to achieve acceptance of Lifecore's new products in the
marketplace, and government regulations affecting the companies'
respective business. For additional information about factors that
could cause actual results to differ materially from those
described in the forward-looking statements, please refer to
Lifecore's filings with the Securities and Exchange Commission,
including the risk factors contained in our most recent Quarterly
Report on Form 10-Q and Annual Report on Form 10-K/A.
Forward-looking statements represent management's current
expectations and are inherently uncertain. Except as required by
law, neither company undertakes any obligation to update
forward-looking statements made to reflect subsequent events or
circumstances.
View original
content:https://www.prnewswire.com/news-releases/shl-medical-and-lifecore-biomedical-enter-co-marketing-partnership-agreement-301958013.html
SOURCE SHL Medical